Amalgamated Bank Galectin Therapeutics Inc Call Options Transaction History
Amalgamated Bank
- $11.7 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding GALT
# of Institutions
113Shares Held
10.2MCall Options Held
3.78MPut Options Held
5.27M-
Vanguard Group Inc Valley Forge, PA2.14MShares$2.76 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$2.02 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$1.52 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA871KShares$1.12 Million0.0% of portfolio
-
Geneos Wealth Management Inc.427KShares$551,3910.01% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $76.7M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...